Ingenza’s ambitious SYNBIOPRO project for the development of biopharmaceuticals continues to make significant progress, despite the global disruption caused by the COVID-19 pandemic. Supported by a Scottish Enterprise research and development (R&D) grant since 2018, this project has hit a…
The COVID-19 pandemic has brought the world to a standstill this year but, at Ingenza, we’ve tried to remain positive throughout and keep spirits high amongst the team. We are pleased to have been able to operate as normally as…
My route into science was less traditional than most. I joined Ingenza straight from high school in January 2012, choosing to take on a modern apprenticeship rather than starting a full-time degree. This work-based learning approach was a more appealing…
I have always been interested in figuring out how things work and solving problems, which is what initially led me to study chemistry at university. I then decided to pursue a PhD in biochemistry at the University of Strathclyde, followed…
Ingenza has reached an important milestone in its work to develop a low cost recombinant human factor VIII (rhFVIII) production process to make materials for ProFactor Pharma Ltd (PFP). The goal of this work is to enable PFP to transform…
Edinburgh-based biotech company Ingenza Ltd. has made a significant breakthrough in the race to develop and manufacture a cost-effective vaccine against SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. Ingenza has been working closely with researchers at Oxford University…
Fermentation is essential for scaling up bioprocesses in the sustainable manufacture of chemicals, biologics, pharmaceuticals and biofuels and, here at Ingenza, our richly diverse, multidisciplinary team has built up a wealth of experience to help you do just that. We…
Edinburgh-based Ingenza, a leader in the application of biotechnology, has increased its footprint to over 12,000 sq ft within the Roslin Innovation Centre. This has allowed it to invest in additional bioprocessing equipment, supporting its upcoming project for the development…
I joined Ingenza in 2009 as a graduate in biomedical sciences. Five years later, with some industrial experience behind me, I decided that I would like to do a PhD, ideally while continuing to work at Ingenza. However, although there…
Biopharmaceuticals now account for a significant proportion of new drugs being released onto the market, providing alternative treatment strategies for many medical conditions, as well as offering new hope for previously untreatable or orphan diseases. Unlike the manufacture of small…